Metrics cut 1
- FY27 gross margin guidance cut to ~59% (from 60-61% earlier)
Event Participants
Executives
6 Piyush Nahar, Samit Mehta, Satish Ramanlal Mehta, Saurabh Paliwal, Tajuddin Sabir Shaikh, Vikas Madan Thapar
Analysts
6 Alankar Garude, Alok Dalal, Ankush Mahajan, Foram Parekh, Kunal Randeria, Tushar Manudhane
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹2,580 crores | +22.8% YoY, broad-based growth across domestic and international markets |
| Domestic Revenue | ₹1,095 crores | +10.2% YoY (India), +12.3% vs Q4 FY26; CNS, cardiology, gynecology brands led growth |
| International Revenue | ₹1,485 crores | +34.2% YoY; constant currency growth ~12% (forex impact ~6%) |
| Europe Revenue | ₹537 crores | +32.8% YoY; led by liposomal Amphotericin B scale-up and base business |
| Canada Revenue | ₹427 crores | +24.6% YoY; continued base business growth, market share gains |
| ROW Revenue | ₹522 crores | +44.8% YoY; ARV/HIV business strong; ARV ~65% of ROW in Q1, ~50-55% for full year |
| Gross Profit | ₹1,507 crores | +16.1% YoY; Gross margin 58.4%, down YoY on export/product mix |
| R&D Investment | ₹90 crores | 3.5% of revenue; expected to pick up to 4-5% for FY27 |
| EBITDA | ₹508 crores | +25.8% YoY; margin 19.7%, +50 bps YoY on operating leverage and productivity gains |
| PAT | ₹292 crores | +35.4% YoY; PAT margin improved 110 bps YoY |
| Depreciation & Amortization | ₹110 crores | Up from ₹99 crores in Q1 FY26 |
| Interest Cost | ₹32 crores | — |
| Effective Tax Rate | 25.6% | — |
| Gross Debt | ₹1,291 crores | As on 30th June |
| Cash & Equivalents | ₹189 crores | — |
| Net Debt | ₹1,103 crores | Expected to rise ~₹450-500 crores in Q2 FY27 on Mantra/Gennova payouts |
Geographic & Segment Commentary
India Domestic: Revenue ₹1,095 crores, +10.2% YoY and +12.3% QoQ vs Q4 FY26. Leading brands across CNS, cardiology, gynecology showed strong traction. Zuventus restructuring progressing through stability and consolidation phases, now moving toward acceleration. In-licensed products (Sanofi OAD, Roche nephro, Novo Nordisk Poviztra) complemented own-brand performance. Organic growth ex-Sanofi/Roche was ~6-7%, impacted by Zuventus consolidation in base. Company guiding to industry-par growth in Q2 and faster-than-industry in 2H FY27.
Europe: Grew 32.8% to ₹537 crores. Growth driven by Liposomal Amphotericin B ramp-up across all European countries (tender-based procurement cycles) and steady base business execution. Management expects continued high-profile pipeline product contributions; upcoming filings expected to add momentum.
Canada: Grew 24.6% to ₹427 crores. Broad-based growth across base business with no single big-hitter product concentration. Semaglutide filing planned in Q2 FY27 (second wave). Quebec launch timeline deferred to Dr. Reddy's following their product recall issue.
Rest of World (ROW): Grew 44.8% to ₹522 crores, the fastest-growing region. ARV/HIV business drove Q1 growth (~65% of ROW), with non-ARV also contributing. Full-year mix expected ~50-55% ARV. Management sees continued growth in both ARV and non-ARV segments, not a FY27 spike followed by flattening.
Company-Specific & Strategic Commentary
Leadership Transition: Chairman Berjis Desai stepping down post-AGM (appointed Member of National Commission of Minorities, Government of India). Satish Mehta to become Chairman & CEO. Samit Mehta appointed COO of Emcure and CEO of Gennova, signaling next-generation leadership shift.
Gennova Full Ownership: Acquired 12.06% minority stake, making Gennova a 100% owned subsidiary. This simplifies group structure (Gennova, Zuventus all fully owned) and sharpens focus on biosimilars and biologics platforms. Biosimilar pipeline considered strategically critical for long-term growth.
Differentiated Pipeline: 15+ product approvals received in Q1 FY27 across developed and emerging markets. ICMR licensed novel anti-HPV NCE candidate for cervical neoplasia (July), aligned with women's healthcare portfolio. Signed royalty-free, non-exclusive voluntary licensing agreement with Merck Sharp & Dohme for generic once-monthly oral HIV PrEP candidate Alimatravir in 129 low/lower-middle-income countries, complementing existing Gilead Lenacapavir licensing.
In-Licensing & Innovation Strategy: 30-35% of domestic sales from R&D-developed products (ferrous ascorbate, ferric carboxymaltose, Tenecteplase etc.). Strategy focused on three levers: making big brands bigger, R&D-driven portfolio, and in-licensing from multinationals plus early-stage ICMR products.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | Low to mid-teens; tracking to higher end | Q1 strength and visibility on ARV order book support higher-end confidence; mix shift toward international impacts gross margin |
| EBITDA Margin Expansion | 70-100 bps for FY27 | Operating leverage and productivity gains; Q1 delivered +50 bps |
| Gross Margin | ~59% for FY27 | Down from earlier 60-61% expectation due to stronger international/ARV mix (B2B, lower GM but accretive at EBITDA level) |
| R&D Investment | 4-5% of revenue for FY27 | Q1 at 3.5%; ramp-up expected through the year to support pipeline |
| Net Debt | ~₹1,450 crores by end of Q2 FY27 | Includes ~₹450-500 crores Mantra & Gennova payouts completed in July; working capital normalized |
| Net Cash Position | By end of FY28 | CFO target based on deleveraging trajectory; currently ₹1,103 crores net debt |
| India Growth Trajectory | Q2 in line with industry; 2H faster than industry | Zuventus consolidation complete; base effects from 2H FY26 slowdown support acceleration |
Risks & Constraints
| Risk | Context |
|---|---|
| Semaglutide Market Chaos | 40-50 brands launched in India; uncertainty around channel stuffing vs real consumption. CEO: "jury is out" on 3-6 month outlook. Emcure sees month-over-month Poviztra growth, MASH approval adds clinical tailwind. Competitive survival of the fittest expected. |
| Dr. Reddy's Recall Impact on Quebec Launch | Dr. Reddy's faced product issue delaying semaglutide relaunch in Canada (possible November). Emcure Quebec launch timeline deferred to Reddy's supply. Management comfortable with portfolio diversification in Canada. |
| Zuventus Restructuring Execution | Q1 FY26 saw sales force exodus. Management claims stability and consolidation achieved; acceleration now underway. Organic India growth was ~6-7% due to this disruption; full-year alignment with industry growth assumes successful execution. |
| ROW ARV Concentration | ARV ~65% of ROW revenue in Q1 creates geographic/therapy concentration risk. Full-year mix guided to 50-55%, but strong ARV growth could skew mix lower-margin, affecting gross margin profile. |
| Gross Margin Compression | International mix shift (Europe/ARV B2B) pulled gross margin to 58.4% (down YoY). FY27 GM guided ~59% vs historical 60%+. Trade-off: higher top-line growth at lower GM but EBITDA-accretive. |
Q&A Highlights
India Domestic Growth Quality
- Question: Is the 10.2% India growth clean, or does it include channel filling after Q4? (Kunal Randeria - Axis Capital)
- Answer: This is normalized growth, no channel filling. Growth expected to improve further from current levels in coming quarters. (Vik Thapar)
In-Licensed Portfolio Contribution
- Question: How much revenue contribution from in-licensed products (Sanofi, Roche, Poviztra) and how are they growing? (Kunal Randeria - Axis Capital)
- Answer: Most in-licensed products grow in line with industry. Faster industry-level growth driven by own brands in Women's Health, cardio, CNS, oncology. (Vik Thapar)
ROW ARV Sustainability
- Question: ROW at 45% growth off a 42% high base — will FY28 be subdued? ARV contribution? (Kunal Randeria - Axis Capital)
- Answer: Growth seen in both ARV and non-ARV; no expectation of FY27 spike flattening. ARV ~65% of ROW in Q1, ~50-55% for full year. (Vik Thapar)
Zuventus Restructuring Progress
- Question: Quantify where we are in the Zuventus journey — 60%, 70%? (Alankar Garude - Kotak Institutional Equities)
- Answer: Three phases — stability (achieved), consolidation (completed), acceleration (underway). Zuventus no longer a concern; new team well-trained, moving toward high growth. (Satish Mehta). From Q2 onwards, India growth in line with industry; 2H faster than industry on base effects. (Vik Thapar)
Organic India Growth Breakdown
- Question: Excluding Sanofi OAD, Roche nephro, Poviztra — what was organic India growth range? (Alankar Garude - Kotak)
- Answer: ~6-7% ex Sanofi and Roche. Poviztra is effectively a new launch. When comparing to industry in Q2+, OAD falls into base; Roche is small. (Vik Thapar)
Semaglutide Market Traction
- Question: What is your view on semaglutide market pickup — channel inventory, slower traction reports? (Alankar Garude - Kotak)
- Answer: Innovator molecule approved for MASH 15 days ago — potential pole position. ~40-50 brands launching; channel stuffing vs real consumption is "jury out" for 3-6 months. Poviztra growing month-over-month; competitive pricing vs innovator; survival of the fittest expected. (Satish Mehta)
Constant Currency Growth
- Question: Constant currency growth for exports? (Alok Dalal - Jefferies)
- Answer: Overall company forex impact ~6-7%; international constant currency ~12%. (Vik Thapar)
Europe/Canada Growth Composition
- Question: Will Europe/Canada growth be broad-based or driven by 1-2 products like ampho? (Alok Dalal - Jefferies)
- Answer: Europe more concentrated with high-profile pipeline products; Canada is broad-based, no big-hitter concentration. Ampho launched in all European countries, ramping supplies; UK retail presence adds plain-vanilla generic contributions. (Piyush Nahar, Vik Thapar)
Semaglutide Canada Filing Timeline
- Question: Timeline for semaglutide filing in Canada? (Alok Dalal - Jefferies)
- Answer: Filing in current quarter (Q2 FY27). Semaglutide was part of global development, tagging along with domestic; delay due to discussions on expanding development. Second-wave entry; will be one of portfolio products, not a meaningful standalone growth driver in Canada. (Vik Thapar, Piyush Nahar)
Gross Margin Outlook
- Question: Where does gross margin settle given Europe/Canada scaling — FY27/FY28? (Tushar Manudhane - Motilal Oswal)
- Answer: FY27 ~59%. FY27 started with guidance of 60-61% GM; stronger international/ARV performance (B2B model, lower GM but EBITDA-accretive) pulls mix down. Top-line guidance now at higher end of low-to-mid teens. (Vik Thapar, Piyush Nahar)
India Growth Price/Volume Split
- Question: Breakdown India growth into price, volume, new launches? (Tushar Manudhane - Motilal Oswal)
- Answer: New launches ~1-2%; price ~4-5%; remainder volume. (Vik Thapar)
Poviztra Market Share
- Question: Response from market for Poviztra vs generics; market share building? (Ankush Mahajan - Sanctum Wealth)
- Answer: Traction month after month; early days. MASH approval enables approaching hepatologists/gastroenterologists. Innovation, innovator DNA molecule, clinical data support emergence as one of bigger players. (Satish Mehta)
Net Debt Strategy
- Question: Debt repayment strategy; net cash timeline? (Foram Parekh - BOB Capital Markets)
- Answer: Net cash by end of FY28. Q2 debt increase ~₹450-500 crores from Mantra and Gennova payouts. Working capital captured in Q1 is stabilized; net debt ~₹1,450 crores by end of next quarter. (Taj Shaikh)
R&D Spend Guidance
- Question: R&D expense guidance for FY27? (Foram Parekh - BOB Capital Markets)
- Answer: Full year in 4-5% revenue range; Q1 at 3.5%, ramp-up through year. (Vik Thapar)
Quebec Semaglutide Launch Timeline
- Question: Post Dr. Reddy's issue, revised timelines for Quebec semaglutide launch? (Alankar Garude - Kotak)
- Answer: Defer to Reddy's on timeline; launch when product available. Whether Quebec launches simultaneously with rest of Canada depends on Reddy's supply. (Vik Thapar)
Co-Prescription Strategy
- Question: Emcure's covered market and prescriptions per doctor lower than peers; how will licensing deals change this? (Alankar Garude - Kotak)
- Answer: In-licensed deals bring strong legacy brands with entrenched prescription habits; complementarity with Emcure portfolio should drive co-prescriptions up. Domestic strategy: make big brands bigger, R&D-driven products (30-35% of sales), plus MNC in-licensing. (Vik Thapar, Satish Mehta)
Key Takeaway
Emcure delivered a strong Q1 FY27 with revenue of ₹2,580 crores (+22.8% YoY), EBITDA margin at 19.7% (+50 bps), and PAT of ₹292 crores (+35.4% YoY), with international markets (+34.2%) overwhelming driving growth — Europe +32.8%, Canada +24.6%, ROW +44.8% on ARV strength. India returned to double-digit growth (+10.2%) with Zuventus stability achieved and consolidation complete; management guides industry-par growth from Q2 and faster-than-industry in 2H. Strategic moves include acquiring full Gennova ownership (12% minority buyout), appointing Samit Mehta as COO/CEO of Gennova, Satish Mehta's elevation to Chairman, 15+ product approvals, ICMR's anti-HPV NCE license, and MSD voluntary license for once-monthly HIV pill Alimatravir in 129 LMICs. FY27 guidance maintained at low-to-mid-teens revenue growth (tracking to higher end), 70-100 bps EBITDA margin expansion, and R&D at 4-5% of revenue; net cash targeted by end-FY28. Watch items: semaglutide market noise (40-50 brands), Dr. Reddy's supply issues delaying Quebec launch, gross margin settling ~59% on international mix, and net debt rising ~₹450-500 crores in Q2 on acquisition payouts.